This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Upon completion of the program, participants should be able to:
Release Date: April 15, 2022
Expiration Date: April 15, 2023
Estimated time to complete each Module: 30 - 45 minutes
Media: Internet
Computer System Requirements: Internet Connection and Browser
Joseph Eron, MD
Professor of Medicine, School of Medicine
Chief, Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania
Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC
Michelle Cespedes, MD
Associate Professor of Medicine
Division of Infectious Diseases
The Mount Sinai Hospital
New York, New York
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Module 1 (Health Care Disparities in HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Identifying Patients at Risk):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Reducing Risk in Populations at Risk):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Diverse Populations at Risk - Evidence-Based Prevention):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5 (HIV Prevention - What’s on the Horizon):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
e-Newsletter:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all thier financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineleigible company.
Joseph Eron, MD:
|
Helena Kwakwa, MD:
|
Richard Elion, MD:
|
Michelle Cespedes, MD:
|
The PIM planners and others have nothing to disclose.
1) Go to http://www.cmeuniversity.com/
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This program requires HTML 5 enabled web browsers such as: Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs and Janssen Therapeutics, Division of Janssen Products, LP.
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
